Olinvacimab
Based on 1 Customer Validation
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: ≥95.0%
- CAS 番号: 2095504-49-5
- 分子量:148.16 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
IgG1-Vlambda-Ckappa
Human
VEGFR2/KDR/CD309
Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM[1]. Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively[1]. Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK[1]. Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC[1]. Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration[1]. Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures[1]. Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cell (HUVEC) line
-
Concentration:0.5, 1, 5, 10, 20 and 30 μg/mL
-
Incubation Time:30 min
-
Result:Inhibited VEGF-induced phosphorylation of VEGFR-2 and ERK (downstream signaling molecule) in HUVECs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Matrigel-implanted nude mice model[1]
-
Dosage:100 ng
-
Administration:Subcutaneous injection; 100 ng, once
-
Result:Inhibited the neovascularization induced by hVEGF165.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-Vlambda-Ckappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 HUVEC cells with Olinvacimab (HY-P99768, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 2095504-49-5
-
性状 Liquid
-
分子量 148.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Olinvacimab]
-
別名
TTAC-0001; Tanibirumab
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Olinvacimab 関連分類
HY-P99768 関連分類
Powered by Bioz